Biogen (NASDAQ:BIIB) Price Target Raised to $150.00 at HSBC

Biogen (NASDAQ:BIIB) had its price target lifted by HSBC from $143.00 to $150.00 in a report released on Tuesday morning, Marketbeat Ratings reports. HSBC currently has a reduce rating on the biotechnology company’s stock.

BIIB has been the subject of several other research reports. Jefferies Financial Group increased their price target on Biogen from $190.00 to $210.00 and gave the company a “buy” rating in a research note on Friday, November 28th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Biogen in a research note on Monday, December 29th. Barclays started coverage on Biogen in a research report on Thursday, February 19th. They set an “equal weight” rating and a $185.00 target price on the stock. Piper Sandler raised their price target on shares of Biogen from $157.00 to $177.00 and gave the company a “neutral” rating in a research report on Monday, February 9th. Finally, Guggenheim boosted their target price on Biogen from $185.00 to $246.00 and gave the stock a “buy” rating in a research note on Monday, February 9th. Twelve investment analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $205.31.

Biogen Stock Up 1.1%

Biogen stock opened at $185.29 on Tuesday. Biogen has a twelve month low of $110.04 and a twelve month high of $202.41. The company’s 50-day moving average price is $184.32 and its two-hundred day moving average price is $167.92. The company has a quick ratio of 2.03, a current ratio of 2.68 and a debt-to-equity ratio of 0.34. The stock has a market cap of $27.19 billion, a P/E ratio of 21.03, a P/E/G ratio of 1.45 and a beta of 0.15.

Biogen (NASDAQ:BIIB) last issued its quarterly earnings data on Friday, February 6th. The biotechnology company reported $1.99 earnings per share for the quarter, topping the consensus estimate of $1.61 by $0.38. Biogen had a net margin of 13.07% and a return on equity of 12.64%. The business had revenue of $2.28 billion during the quarter, compared to analysts’ expectations of $2.21 billion. During the same quarter in the previous year, the company earned $3.44 EPS. The business’s revenue was down 7.2% on a year-over-year basis. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. As a group, analysts expect that Biogen will post 15.83 EPS for the current year.

Insider Activity at Biogen

In related news, insider Priya Singhal sold 2,660 shares of Biogen stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $199.83, for a total transaction of $531,547.80. Following the sale, the insider directly owned 8,043 shares in the company, valued at $1,607,232.69. The trade was a 24.85% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.18% of the stock is currently owned by insiders.

Institutional Trading of Biogen

Hedge funds and other institutional investors have recently modified their holdings of the business. Reflection Asset Management bought a new stake in shares of Biogen in the 4th quarter worth approximately $25,000. WPG Advisers LLC increased its position in Biogen by 417.9% during the 4th quarter. WPG Advisers LLC now owns 145 shares of the biotechnology company’s stock valued at $26,000 after buying an additional 117 shares in the last quarter. First Horizon Corp purchased a new position in Biogen during the fourth quarter valued at $30,000. Root Financial Partners LLC boosted its holdings in Biogen by 198.4% in the fourth quarter. Root Financial Partners LLC now owns 185 shares of the biotechnology company’s stock worth $33,000 after acquiring an additional 123 shares in the last quarter. Finally, MV Capital Management Inc. purchased a new stake in shares of Biogen in the fourth quarter worth $34,000. 87.93% of the stock is owned by hedge funds and other institutional investors.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.